Q3 results on Jan 31, 2017
Cadila Healthcare Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on January 31, 2017 to consider inter alia, to approve the un-audited financial results for the quarter / nine months ended on December 31, 2016 (Q3).Further, as per Code of Conduct for prevention of Insider Trading adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window shall remain... Cadila Healthcare: US FDA resolution key for re-rating
Recent brand acquisition will help boost domestic sales US FDA pulls up Cadila for misbranding drug
US FDA pulls up Cadila for misbranding drugThe company has been researching on the drug to treat fatty liver disease or non-alcoholic steatohepatitis apart from diabetic dyslipidemia. Zydus acquires six brands from MSD
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated December 28, 2016 titled "Zydus acquires six brands from MSD". Clarification
Cadila Healthcare Ltd has informed BSE that :"With reference to a news appearing in the media this morning, we wish to state as under:We wish to clarify that this matter very specifically relates to an Untitled Letter issued by the USFDA to Zydus Discovery DMCC (a 100% subsidiary of Cadila Healthcare Ltd.) and not a Warning Letter. The letter is related to a product promotion of a drug which is not marketed in USA and currently marketed... Zydus Announces Settlement of a DELZICOL (mesalamine) Patent Litigation
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated December 03, 2016 titled "Zydus Announces Settlement of a DELZICOL (mesalamine) Patent Litigation". Cadila Healthcare Ltd reply to clarification sought by the exchange
The Exchange had sought clarification from Cadila Healthcare Ltd with reference to the media report titled, "Vietnam Bans 39 Indian Drug Cos for Violating Quality Standards." Cadila Healthcare Ltd response is enclosed. Clarification sought from Cadila Healthcare Ltd
The Exchange has sought clarification from Cadila Healthcare Ltd with respect to news article appearing in Economic Times on November 23, 2016 titled "Vietnam Bans 39 Indian Drug Cos for Violating Quality Standards." The reply is awaited. Zydus Cadila Gets USFDA Nod For Anti-Infections Tablets
Zydus Cadila has received final approval from the US health regulator to market its Metronidazole tablets used for the treatment of infections caused by bacteria or parasites. Zydus receives final approval from the USFDA for Metronidazole Tables
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated November 21, 2016 titled "Zydus receives final approval from the USFDA for Metronidazole Tables".